08:00 , Mar 5, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CD36 (GPIV); macrophage scavenger receptor 1 (MSR-1; SR-A; CD204)

Cardiovascular disease INDICATION: Atherosclerosis In vitro and mouse studies suggest sugar-based amphiphilic nanoparticles could help treat atherosclerosis. Macrophage recruitment and oxidized low-density lipoprotein (LDL) uptake via scavenger receptors such as CD36 and MSR-1 contributes to...
08:00 , Dec 12, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HIV/AIDS CD36 (GPIV) In vitro studies suggest anti-CD36 antibodies could help treat HIV. In HIV-infected macrophages, an anti-CD36 mAb or...
08:00 , Nov 14, 2011 |  BC Week In Review  |  Clinical News

Arteria preclinical data

In mice and rats, oral AP-5258 significantly inhibited the transfer of postprandial triglycerides vs. an inactive control (p<0.01). Arteria plans to start a Phase I trial of the CD36 (GPIV) inhibitor next year. Arteria S.A....